Literature DB >> 28057385

Evaluating the first introduction of rotavirus vaccine in Thailand: Moving from evidence to policy.

Piyanit Tharmaphornpilas1, Suchada Jiamsiri2, Somchit Boonchaiya2, Onwipa Rochanathimoke3, Wiravan Thinyounyong4, Sumana Tuntiwitayapun5, Ratigorn Guntapong6, Arthorn Riewpaiboon3, Aim-On Rasdjarmrearnsook2, Roger I Glass7.   

Abstract

BACKGROUND: We assessed the effectiveness and possible impact of introducing rotavirus vaccine into the routine immunization program.
METHODS: Two provinces were selected for an observational study, one where vaccine was introduced and another where vaccine was not available. In these areas, two sub-studies were linked. The prospective cohort study enrolled children 2month old and followed them to the age of 18months to detect all diarrhea episodes. The hospital surveillance study enrolled all children up to age 5 hospitalized with diarrhea whose fecal samples were tested for rotavirus. Rates of rotavirus hospitalizations in older children who had not been vaccinated in both settings provided data to determine whether immunization had an indirect herd effect. The key endpoints for the study were both vaccine effectiveness (VE) based upon hospitalized rotavirus diarrhea and herd protection.
FINDINGS: From the cohort study, the overall VE for hospitalized rotavirus diarrhea was 88% (95%CI 76-94). Data from hospital surveillance indicated that for 2 consecutive years, the seasonal peak of rotavirus admissions was no longer present in the vaccinated area. Herd protection was observed among older children born before the rotavirus vaccine program was introduced, who experienced a 40-69% reduction in admission for rotavirus.
CONCLUSIONS: Rotavirus vaccine was highly effective in preventing diarrheal hospitalizations and in conferring herd protection among older children who had not been vaccinated.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Rotavirus vaccine; Vaccine effectiveness; Vaccine impact

Mesh:

Substances:

Year:  2017        PMID: 28057385     DOI: 10.1016/j.vaccine.2016.12.043

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Landscape of vaccine access and health technology assessment role in decision-making process in ASEAN countries.

Authors:  Suthira Taychakhoonavudh; Woralak Chumchujan; Raymond Hutubessy; Nathorn Chaiyakunapruk
Journal:  Hum Vaccin Immunother       Date:  2020-06-23       Impact factor: 3.452

2.  Estimated impact of rotavirus vaccine on hospitalizations and deaths from rotavirus diarrhea among children <5 in Asia.

Authors:  Eleanor Burnett; Jacqueline E Tate; Carl D Kirkwood; E Anthony S Nelson; Mathuram Santosham; A Duncan Steele; Umesh D Parashar
Journal:  Expert Rev Vaccines       Date:  2018-02-26       Impact factor: 5.217

3.  Burden and pattern of acute diarrhea in Thai children under 5 years of age: a 5-year descriptive analysis based on Thailand National Health Coverage (NHC) data.

Authors:  Busara Charoenwat; Kunanya Suwannaying; Watuhatai Paibool; Napat Laoaroon; Sumitr Sutra; Kaewjai Thepsuthammarat
Journal:  BMC Public Health       Date:  2022-06-10       Impact factor: 4.135

4.  Economic Evaluation of Human Rotavirus Vaccine in Thailand.

Authors:  Surasak Saokaew; Wasana Prasitsuebsai; Gyneth Lourdes Bibera; Kirati Kengkla; Xu-Hao Zhang; Kyu-Bin Oh; Christa Lee
Journal:  Infect Dis Ther       Date:  2019-06-13

5.  Full genome characterization of novel DS-1-like G9P[8] rotavirus strains that have emerged in Thailand.

Authors:  Saori Fukuda; Ratana Tacharoenmuang; Ratigorn Guntapong; Sompong Upachai; Phakapun Singchai; Tomihiko Ide; Riona Hatazawa; Karun Sutthiwarakom; Santip Kongjorn; Napa Onvimala; Kriangsak Ruchusatsawast; Pimpa Rungnopakun; Jutarat Mekmallika; Yoshiki Kawamura; Kazushi Motomura; Masashi Tatsumi; Naokazu Takeda; Takayuki Murata; Tetsushi Yoshikawa; Ballang Uppapong; Koki Taniguchi; Satoshi Komoto
Journal:  PLoS One       Date:  2020-04-22       Impact factor: 3.240

Review 6.  Rotavirus infection in children in Southeast Asia 2008-2018: disease burden, genotype distribution, seasonality, and vaccination.

Authors:  Fajar Budi Lestari; Sompong Vongpunsawad; Nasamon Wanlapakorn; Yong Poovorawan
Journal:  J Biomed Sci       Date:  2020-05-21       Impact factor: 8.410

7.  High prevalence of circulating DS-1-like human rotavirus A and genotype diversity in children with acute gastroenteritis in Thailand from 2016 to 2019.

Authors:  Siripat Pasittungkul; Fajar Budi Lestari; Jiratchaya Puenpa; Watchaporn Chuchaona; Nawarat Posuwan; Jira Chansaenroj; John Mauleekoonphairoj; Natthinee Sudhinaraset; Nasamon Wanlapakorn; Yong Poovorawan
Journal:  PeerJ       Date:  2021-02-26       Impact factor: 2.984

8.  Priority setting for the introduction of rotavirus vaccine: what evidence was essential?

Authors:  Roger I Glass
Journal:  Cost Eff Resour Alloc       Date:  2018-11-09

9.  The impact of the rotavirus vaccine on diarrhoea, five years following national introduction in Fiji.

Authors:  Adam W J Jenney; Rita Reyburn; Felisita T Ratu; Evelyn Tuivaga; Cattram Nguyen; Sokoveti Covea; Sarah Thomas; Eric Rafai; Rachel Devi; Kathryn Bright; Kylie Jenkins; Beth Temple; Lisi Tikoduadua; Joe Kado; E Kim Mulholland; Carl D Kirkwood; Kimberley K Fox; Julie E Bines; Varja Grabovac; Aalisha Sahu Khan; Mike Kama; Fiona M Russell
Journal:  Lancet Reg Health West Pac       Date:  2020-11-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.